Evogene Ltd. Schedules 2024 Annual Shareholder Meeting
Ticker: EVGN · Form: 6-K · Filed: Apr 30, 2024 · CIK: 1574565
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing
TL;DR
Evogene's shareholder meeting is set for June 6th. Vote wisely.
AI Summary
Evogene Ltd. announced its 2024 annual general meeting of shareholders will be held on Thursday, June 6, 2024, at 3:00 p.m. Israel time at its offices. The company is a foreign private issuer filing a Form 6-K report for the month of April 2024, indicating it will file its annual reports under cover of Form 20-F.
Why It Matters
This filing informs shareholders about the upcoming annual meeting where key corporate decisions and elections will be made, impacting the company's future direction.
Risk Assessment
Risk Level: low — This is a routine corporate filing announcing a shareholder meeting, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- June 6, 2024 (date) — Date of Annual General Meeting
FAQ
When and where will Evogene Ltd.'s 2024 annual general meeting of shareholders take place?
The meeting is scheduled for Thursday, June 6, 2024, at 3:00 p.m. Israel time, at Evogene's offices.
What form does Evogene Ltd. use for its annual reports?
Evogene Ltd. files its annual reports under cover of Form 20-F.
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer for the month of April 2024, publishing a notice of its 2024 annual general meeting of shareholders.
What is Evogene Ltd.'s principal executive office address?
The principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
What is the Commission File Number for Evogene Ltd.?
The Commission File Number for Evogene Ltd. is 001-36187.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-04-30 16:00:29
Filing Documents
- zk2431353.htm (6-K) — 14KB
- exhibit_99-1.htm (EX-99.1) — 22KB
- exhibit_99-2.htm (EX-99.2) — 252KB
- exhibit_99-3.htm (EX-99.3) — 27KB
- image0.jpg (GRAPHIC) — 282KB
- image00001.jpg (GRAPHIC) — 266KB
- 0001178913-24-001488.txt ( ) — 1070KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Notice, Proxy Statement and Proxy Card for Annual General Meeting of Shareholders Evogene Ltd. (" Evogene ") hereby publishes a notice of its 2024 annual general meeting of shareholders (the " Meeting "), which is scheduled to take place at 3:00 p.m. (Israel time) on Thursday, June 6, 2024, at Evogene's offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel. Shareholders of record at the close of business on Friday, May 3, 2024, are entitled to vote at the Meeting. Attached as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") is the Notice of 2024 Annual General Meeting of Shareholders, which contains information concerning the agenda for the Meeting, the required majority for approval of the proposals at the Meeting, the voting procedure and additional general matters related to the Meeting. Attached as Exhibit 99.2 to this Form 6-K is the Proxy Statement for the Meeting, which describes in greater detail each of the proposals to be presented at the Meeting, including background information related to the proposals, additional logistical information concerning the required vote and means of voting on the proposals, and general information concerning Evogene's board of directors and corporate governance. Attached as Exhibit 99.3 to this Form 6-K is the form of proxy card being distributed by Evogene to its shareholders of record as of the record date for the Meeting, which serves as the primary means for those shareholders to cast their votes on the proposals to be presented at the Meeting. The contents of Exhibits 99.1, 99.2 and 99.3 to this Form 6-K are incorporated by reference in the registration from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibits No. 99.1 Notice for the 2024 Annual General Meeting of Evogene Ltd. to be held on June 6, 2024 99.2 Proxy Statement for the 2024 Annual General Meeting of Evogene Ltd. 99.3 Proxy Card to be distributed to record shareholders of Evogene Ltd. to cast their vote at the 2024 Annual General Meeting of Evogene Ltd. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: April 30, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer